Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Merck Isentress – Emerging Therapy for Treatment of HIV Infection

Drug (Brand/Generic)

Isentress (raltegravir)

Company/Licensee

Merck

Therapy Class

Integrase inhibitor

Product Description

Anti-retroviral drug that blocks the action of HIV integrase enzyme

Current Indication

Treatment of HIV as part of background HIV therapy

Market Sector

Anti-infectives

Development Status

Approved US and Europe
Expand
Close
Close
Close

Go Top